THURSDAY, Feb. 18, 2021 (HealthDay Information) — Customers of terazosin, doxazosin, or alfuzosin are at decrease danger for creating Parkinson illness (PD) in contrast with customers of tamsulosin, in response to a examine revealed on-line Feb. 1 in JAMA Neurology.
Jacob E. Simmering, Ph.D., from the College of Iowa in Iowa Metropolis, and colleagues assessed whether or not use of terazosin, doxazosin, and alfuzosin is related to a decreased danger for creating PD versus use of tamsulosin. The evaluation included 52,365 propensity score-matched pairs of terazosin/doxazosin/alfuzosin customers and tamsulosin customers recognized in Danish registries and 94,883 propensity score-matched pairs recognized within the U.S. Truven database.
Sufferers within the Danish cohort who used terazosin/doxazosin/alfuzosin had a decrease danger for creating PD (hazard ratio [HR], 0.88; 95 p.c confidence interval [CI], 0.81 to 0.98), as did sufferers within the Truven cohort (HR, 0.63; 95 p.c CI, 0.58 to 0.69). A dose-response affiliation was detected, with higher danger discount tied to longer use of terazosin/doxazosin/alfuzosin within the Danish cohort (short-term use: HR, 0.95; 95 p.c CI, 0.84 to 1.07; medium-term use: HR, 0.88; 95 p.c CI, 0.77 to 1.01; long-term use: HR, 0.79; 95 p.c CI, 0.66 to 0.95) and within the Truven cohort (short-term use: HR, 0.70; 95 p.c CI, 0.64 to 0.76; medium-term use: HR, 0.58; 95 p.c CI, 0.52 to 0.64; long-term use: HR, 0.46; 95 p.c CI, 0.36 to 0.57).
“Regardless of the relative variations in inhabitants and well being care system construction, we discovered an analogous protecting impact in each nations,” Simmering mentioned in an announcement. “The replication of the discovering in a world cohort is highly effective proof suggesting a causal impact.”